Fig. 1: Levosulpiride improved the change from baseline in visual and structural parameters.
From: Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial
Changes from baseline in best-corrected visual acuity (BCVA) (A), central foveal thickness (CFT) (C), and mean macula volume (MMV) (E) through 8 weeks of treatment with placebo (P, 18 eyes, white circles) or levosulpiride (L, 22 eyes, black circles). Mean ± SEM and individual values are indicated by big and small circles, respectively. Some individual values are identical and, thereby, hidden behind those shown. Comparisons (t-test) between same week L and P values are indicated. Proportion of eyes with different outcomes in BCVA (B), CFT (D), and MMV (F) after 8 weeks of treatment with P (18 eyes) or L (22 eyes).
